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ABSTRACT 
 
Aim:  
Evaluation of the protective effect of hydro-alcoholic extract of the fruit peels of Punica 
granatum Linn against ulcerative colitis in rats. 
Methods:  
Acute oral toxicity study was performed to find out the test dose according to OECD 
guidelines 425 and hydro-alcoholic extract of P. granatum fruit peel (PGPE) was found to be 
safe at a dose of 2000 mg/kg body weight. The acetic acid induced colitis and 
Trinitrobenzene sulfonic acid (TNBS) induced colitis models were used to evaluate the 
protective effect of extract against colitis. 
Results: 
The animals pretreated with hydro-alcoholic extract of P. granatum fruit peel (200 mg/kg and 
400 mg/kg respectively) significantly restored the altered hematological, biochemical 
parameters to normal levels when compared with control. The protective effect of P. 
granatum peel extract was comparable to standard sulfasalazine. 
Conclusion: 
The findings of the present study revealed that the hydro-alcoholic extract of P. granatum 
fruit peel possessed a dose dependent significant inhibitory activity against ulcerative colitis. 
The results obtained established the efficacy of the Punica granatum fruit peel against 
inflammatory bowel diseases possibly by its anti-inflammatory and antioxidant properties. 
Key words: Ulcerative colitis, Acetic acid, TNBS, Sulfasalazine 
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INTRODUCTION 
 
Inflammatory bowel diseases including ulcerative colitis and Crohn's disease are the most 
affecting human illness
1
, are chronic inflammatory bowel disease
2
. Inflammatory bowel 
disease is an immune-mediated disease of the gastrointestinal tract caused by ulceration and 
inflammation
3
.Crohn’s disease (CD) and ulcerative colitis(UC).The pathogenesis of IBD is a 
multi factorial process
4
. In addition, the progress of an unusual immune and inflammatory 
reaction occurs, which is mediated mostly by activated neutrophils, monocytes, and 
macrophages and characterized by an increased development of reactive oxygen and nitrogen 
species. Different pro inflammatory cytokines such as interleukins (IL)-1, IL-6 and tumor 
necrosis factor alpha (TNF-α) chemo lines and union molecules are known to contribute to 
the pathogenesis of IBD
5
. 
Ulcerative colitis, moreover known as chronic ulceration of the intestines, is a universal 
disease estimated to have an incidence of 1 in 1000 persons in western countries
6
. Effective 
treatment relies on correct and timely diagnosis. Various factors contribute to the disease’s 
clinical manifestations, including psychiatric and physical components, but the etiology of 
the disease remains poorly understood
7-8
.  
The majority of the current treatments for inflammatory bowel disease include treatment with 
glucocorticosteriods and 5-aminosalicyclic acid. Immunosuppressive drugs have also been 
used to heal chronic illness, regardless of the more dangerous complications and hazardous 
side effect associated with them
9
. 
Colon ulcer (ulcerative colitis) is constantly associated with changes in lipid peroxidation, 
Myeloperoxidase activity, catalase activity and glutathione activity. 
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In spite of phenomenal growth of modern medicine, there are few synthetic drugs obtainable 
for the treatment of ulcerative colitis. In allopathic system of treatment, corticosteroids and 
aminosalicylates such as sulfasalazine, mesalamine are mainly used. But these drugs have 
adverse effects such as head ache nausea, temporary male infertility in males etc. 
Disease, decay and death have always co-existed with life, study of diseases and their 
treatment must also have been contemporaneous with the down of human intellect
10
.  
Since ancient time peoples have used herbs and its derivatives as medicines. It is a 
developing practice recorded in both folklore and books of early practitioners. At present, 
despite the abundance and improvement of synthetic drugs, an important proportion of the 
population of developing countries still depend on traditional medicines for their health care 
needs
11
. 
According to WHO, 60% of the world’s population depend on traditional medicine, and 80% 
of the population in developing countries depend almost entirely on traditional medical 
practices, in particular, herbal medicine for their primary health care needs. The long tradition 
of herbal medicine continues to the present day in China, India, and many other countries
12
. 
Medicinal plants continue to contribute significantly to modern prescription drugs by giving 
lead compounds upon which the formation of new drugs can be made. 
In India knowledge of medicinal herbs is very old and medicinal properties of plants are 
included in Rig-Veda and in Atharvaveda (3500-1500 B.C) from which Ayurved has 
developed in Ayurveda. The ancient well-known treatises are Charak Samhita dealing with 
mostly plants and Susrut Sanhita in which surgery is also mentioned. In Egypt, peoples were 
common with medicinal properties of plants and animals. They were familiar with human 
anatomy and knew of embalming the dead and preserving their bodies as described in Ebers 
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Papyrus (1550 B.C) an ancient book found in one of the mummies. Greek scientists 
contributed much to knowledge of natural history. Hippocrates (460-370 B.C) is referred to 
as father of medicine. Theophrastus (370-287 B.C) described medicinal plants, some of 
which like belladonna, ergot, opium, colchicum are used even today
13
. 
Antioxidant agents of natural origin have attracted special interest because they can protect 
human body from free radicals. They are important for better health and are found naturally 
in variety of foods including vegetables and fruits
14
.  
Punica granatum Belongs to the family Punicaceae. It is Native to Iran; but cultivated 
throughout India (Jammu and Himachal Pradesh). 
The plant parts contain phenolic punicalagins; Gallic acid and other fatty acids; catechin, 
quercetin, rutin and other flavonols; flavones, flavonones; anthocyanidins
15
. Also contains 
anti oxidant compounds. That can serve as primary compounds for the development of 
specific drugs for ulcerative colitis. 
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NEED AND OBJECTIVES 
 
Need for the study:  
Hepato toxicity is a comon disease and patients suffering from Various factors contribute to 
the disease’s clinical manifestations, including psychiatric and physical components, but 
etiology of the disease remains poorly understood. The etiology of colitis is multifaceted.  
The drugs of plant origin are gaining increasing popularity and are being investigated for 
remedies of varieties of diseases including hepato toxic protective activity. Ayurveda uses the 
plant, plant products and active ingredients present in plants for treating various diseases. 
Medicinal plants used for ulcerative colitis, in traditional medicine have been shown to 
possess promising cure from ulcerative colitis activities in animal models. There are still 
many more plants yet to be evaluated for above said activity. 
 
Criteria for selection of the plant: 
Number of plants being used for the treatment of hepao toxicity is known to possess 
antioxidants like flavonoids; alkaloids, terpenoids, etc may interact with free radicals and stop 
the injury caused by them.  
Use of polyphenols and flavonoids is beneficial for the prevention of inflammatory disorders. 
pseudarthria viscida is one of such potential plant used for the treatment of ulcerative colitis 
disorders. 
Keeping the above information in view, in the present study attempt was made to evaluate the 
safety and efficacy evaluation of hepato protective effect of methanolic extract of roots of 
pseudarthria viscida. 
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OBJECTIVES OF THE STUDY 
1. Authentication of the plant material and preparation of Herbarium of the sample 
specimen. 
2. To perform extraction of the dried plant material using methanol. 
3. To carry out the preliminary phytochemical screening of the methanolic  extract and 
to detect the classes of compounds present. 
4. To check the in-vivo activity of the roots of Pseudarthria viscida. 
 
I: Identification and Collection 
 Identification, collection and authentication of the pseudarthria viscida root. 
II: Extraction 
Methanolic extract of the dried root and aerial parts of Pseudarthria vicida was taken using 
reflux method5gm in 30 ml for three times and the extracts were clubbed and concentrated to 
dryness using a rotary evaporator. The final volume was make up to 5 ml as the concentration 
was adjusted to 5 gm in 50 ml of methanol. 
III: Preliminary phytochemical screening 
 Preliminary phytochemical screening of methanolic extract. 
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REVIEW OF LITERATURE 
 
3.1      The digestive system
21
. 
The digestive system contributes to homeostasis by breaking down food into forms that can 
be absorbed and used by body cells. It also absorbs water, vitamins, minerals, and eliminates 
wastes from the body. The food we eat contains a variety of nutrients, which are used for 
making new body tissues and repairing injured tissues. Food is also vital to maintain life 
because it is the only source of chemical energy. However, most of the food we eat contains 
molecules that are too large to be used by body cells. Therefore, food must be broken down 
into molecules that are small enough to enter body cells, a process known as digestion. The 
organs involved in the breakdown of food are collectively called as digestive system. Like the 
respiratory system, the digestive system is a tubular system. It extends from the mouth to the 
anus, forms an extensive surface area in contact with the external environment, and is closely 
associated with the cardiovascular system. The combination of extensive environmental 
exposure and close association with blood vessels is essential for processing the food that we 
eat. The medical specialty that deals with the structure, function, diagnosis, and treatment of 
diseases of the stomach and intestines is called gastroenterology (gastro-stomach; entero-
intestines; logy-study of). The medical specialty that deals with the diagnosis and treatment 
of disorders of the rectum and anus is called proctology. 
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Fig 1: Right lateral view of head and neck and anterior view of trunk. 
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3.1.1     Anatomy of the Large Intestine 
21
. 
The large intestine, which is about 1.5 m (5 ft) long and 6.5 cm (2.5 in.) in diameter, extends 
from the ileum to the anus. It is attached to the posterior abdominal wall by its mesocolon, 
which is a double layer of peritoneum structurally; the four major regions of the large 
intestine are the cecum, colon, rectum, and anal canal. 
The opening from the ileum into the large intestine is guarded by a fold of mucous membrane 
called the ileocecal sphincter (valve), which allows materials from the small intestine to pass 
into the large intestine. Hanging inferior to the ileocecal valve is the cecum, a small pouch 
about 6 cm (2.4 in.) long. Attached to the cecum is a twisted, coiled tube, measuring about 8 
cm (3 in.) in length, called the appendix or vermiform. The mesentery of the appendix, called 
the mesoappendix, attaches the appendix to the inferior part of the mesentery of the ileum. 
The open end of the cecum merges with a long tube called the colon (food passage), which is 
divided into ascending, transverse, descending, and sigmoid portions. Both the ascending and 
descending colon are retroperitoneal; the transverse and sigmoid colon are not. True to its 
name, the ascending colon ascends on the right side of the abdomen, reaches the inferior 
surface of the liver, and turns abruptly to the left to form the right colic (hepatic) flexure. The 
colon continues across the abdomen to the left side as the transverse colon. It curves beneath 
the inferior end of the spleen on the left side as the left colic (splenic) flexure and passes 
inferiorly to the level of the iliac crest as the descending colon. The sigmoid colon begins 
near the left iliac crest, projects medially to the midline, and terminates as the rectum at about 
the level of the third sacral vertebra. 
The rectum, the last 20 cm (8 in.) of the GI tract, lies anterior to the sacrum and coccyx. The 
terminal 2–3 cm (1 in.) of the rectum is called the anal canal. The mucous membrane of the 
anal canal is arranged in longitudinal folds called anal columns that contain a network of 
Chapter 3                                                                         REVIEW OF LITERATURE 
 
Dept. of Pharmacology, Padmavathi College of Pharmacy  Page 9 
 
arteries and veins. The opening of the anal canal to the exterior, called the anus, is guarded by 
an internal anal sphincter of smooth muscle (involuntary) and an external anal sphincter of 
skeletal muscle (voluntary). Normally these sphincters keep the anus closed except during the 
elimination of feces 
 
 
       
Fig 2: Anterior view of large intestine showing major regions. 
 
3.1.2    The colon
22
. 
The colon (also called the large bowel) is an organ of the gastrointestinal tract. The job of the 
colon is to absorb fluids, to form stools, and to eliminate stools. The colon is a hollow tube 
surrounded by muscles. It measures about 5 feet long and 2.5 inches in diameter. It has a 
moist interior lining that protects nerves located in the colon wall. 
These nerves send and receive messages to the brain about the colon contents. The brain then 
directs the appropriate colonic action. Fluids and dietary fiber help to maintain colon health. 
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Parts of the Colon, Movement of Waste & Stools 
Several parts make up the continuous tube of the colon. Each part contributes to the 
movement of materials and the formation of stools. The parts include: Ileocecal Valve: The 
ileocecal valve is a fold of mucus membrane at the entry way to the colon. It is located where 
the small intestine meets the colon. Materials from the small intestine pass into the colon 
through this valve. Vermiform Appendix: The appendix is attached to the bottom of the 
cecum. This is a twisted coiled tube that is about 3 inches long. The function of the appendix 
is not known. 
Cecum: The cecum is a kind of reservoir to receive fecal materials as they enter the colon. 
The cecum is located below the ileocecal valve at the base of the colon. The upper part of the 
cecum is open to the colon. The muscles of the cecum and the colon advance feces upward 
out of the cecum. 
Ascending Colon: The ascending colon is located on the right side of the abdomen above the 
cecum. Here, most of the water is absorbed from the feces as it moves upward through the 
ascending colon. The ascending colon ―ends‖ at the hepatic flexure where the colon bends to 
the left and connects to the transverse colon. 
Transverse Colon: The transverse colon runs laterally across the abdomen below the belly 
button. As feces move across the transverse colon, stools begin to take form. The transverse 
colon ―ends‖ at the splenic flexure where the colon bends again and connects to the 
descending colon which heads down the left side.  
Descending Colon: The descending colon runs down the left side of the abdomen. Stools 
move down the descending colon. Stools are now more solid in form. Here, stools may be 
stored for a time. The descending colon ―ends‖ where it continues into the sigmoid colon. 
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Sigmoid Colon: The sigmoid colon angles to the right, curving down and inward to about the 
midline, then it curves slightly upward where it connects to the top of rectum. Stools continue 
their descent as they move through sigmoid colon. Stools may also be stored here for a time 
before they are moved into the rectum. 
Processing & Activity in the Colon 
 
Aided by enzymes and muscular action, the mouth, stomach and small intestine perform their 
individuated jobs of breaking down and absorbing nutrients. The liquid that these organs 
generate is called chyme. This liquid waste matter is called feces. It is passed to the colon for 
further processing and elimination. In the colon, instead of the enzymatic action that occurs in 
other organs of the G.I. tract, further breakdown of fecal matter and the production of 
substances occur by way of bacterial fermentation. Cellular exchanges, bacteria, and 
muscular actions all play a part in processing the feces as it passes through the colon: 
Fluid Absorption: The colon lining contains epithelial cells that absorb fluids and other 
substances such as vitamins and electrolytes. It is the absorption of fluids and bacterial 
processing that transforms the soupy fecal matter into a stool. 
Secretion of Mucous: The colon lining contains epithelial cells that secrete mucus. This 
mucus moisturizes and lubricates the colon lining. This lining protects the colon wall and 
nerve tissues. 
Bacterial Growth: Bacteria live and grow along the colon lining. Using the fluids and foods 
you intake, bacteria actually manufacture the nutrients that sustain their environment and 
their food supply. 
Manufacture of Some Vitamins &Electrolytes: Bacteria change proteins into amino acids 
and break these amino acids down further into indole and skatole (which gives stools their 
odor), hydrogen sulfide, and fatty acids. Bacterial action also synthesizes some vitamins (K 
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and some B), electrolytes, and breaks down bilirubin into a pigment that gives stools their 
brown color. 
Production of Lubrication: Bacteria ferment soluble fiber into a lubricating gel that is 
incorporated into the stool mass as it is formed. This gel helps to make stools soft and 
flexible. Some of this gel also coats the exterior of the stools and is used by the colon to 
moisturize the colon lining. This lubrication helps to ease stool passage through the colon. 
Defense against Infection: Healthy intestinal bacteria help to groom the colon and keep it 
clean so that infections do not develop. They also help to fight the growth of infectious 
bacteria.  
Stool Formation: To form stools, muscles in the colon churn the soupy liquid fecal matter as 
fluids are extracted until the particles have the consistency to form a stool. 
3.2             Inflammatory bowel diseases 
3.2.1          Disease description 
Inflammatory bowel disease (IBD) is a range of chronic idiopathic inflammatory intestinal 
situation. IBD causes significant gastrointestinal symptoms that include diarrhea, abdominal 
pain, bleeding, anemia, and weight loss. IBD also is connected with a spectrum of extra 
intestinal manifestations, including arthritis, uveitis, iritis. IBD mainly divided into two major 
subtypes: 
 Ulcerative colitis 
 Crohn's disease 
Ulcerative colitis is mainly characterized by mucosal inflammation of the colon starting at the 
anal verge and extending proximally for a variable extent. Crohn's disease, is characterized 
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by transmural inflammation of any part of the gastrointestinal tract but most commonly the 
area adjacent to the ileocecal valve
23
. 
Patients with both Ulcerative Colitis and Crohn‘s disease have long been reported to have a 
high risk for colorectal cancer
24
. Although etiology of ulcerative colitis is unknown, but the 
current study suggests that multiple immune, genetic, and environmental factors influence 
both the initiation and multiplication of colitis. There is evidence for an intense local immune 
response along with recruitment of lymphocytes and macrophages followed by discharge of 
soluble cytokines and other inflammatory mediators. Subsequent activation of these cells 
causes a self-augmenting cycle of cytokine production, cell recruitment and inflammation. 
This uncontrolled immune system activation results in a sustained high production of 
cytokines such as tumor necrosis factor (TNF)-α and interleukins (IL-1β and IL-8). In 
addition to cytokines, leukotrienes, thromboxane, platelet-activating factor, nitric oxide and 
reactive oxygen species are also released from activated mucosal cells
25
. 
In ulcerative colitis, only the colon is affected; of the multiple layers of the intestinal wall, 
only the innermost lining of the colon, the mucosa, becomes inflamed in ulcerative colitis 
patients. Ulcerative colitis also spreads proximally, meaning it starts from the rectum and can 
spread continuously to the rest of the large intestine (colon). 
3.2.2    Epidemiology 
In regions with a high prevalence of IBD, such as North America, the incidence was seen to 
increase between the 1960s and 1980s, reaching the current plateau
26–28
. In the United States 
specifically, an estimated 1 million individuals have IBD
29
, with about 30,000 new cases 
reported each year. The incidence is evenly divided between UC and CD
29
. 
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The peak age of onset for IBD is 15 to 30 years old, although it may occur at any age. About 
10% of cases occur in individuals, 18 years old. Both UC and CD have a bimodal age 
distribution, with a second, smaller peak occurring in individual‘s ages 50 to 70 years27, 29. 
Ulcerative colitis is somewhat slightly more common in males, whereas CD is marginally 
more frequent in women (female-to-male ratio range, 1:1 to 1.8:1).Both disorders are tend to 
occur in higher socioeconomic groups
26, 27
. Breakdowns by racial and ethnic subgroups 
indicate that higher rates of IBD occur in people of Caucasian and Ashkenazic Jewish origin 
than in individuals from other backgrounds
26, 30
. The distribution of IBD among ethnic and 
racial groups remains dynamic. In past decades, it was thought that IBD occurred less 
frequently in ethnic or racial minority groups compared with whites. This gap has been 
closing, with an increased incidence in African Americans 
26
 and in second generation south 
Asians who have migrated to developed countries
26, 31
. 
 Most patients are able to live normal, productive lives. Each year in the United States, IBD 
accounts for 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 
patients. Over the long-term, up to 75% of patients with CD and25% to 33% of those with 
UC will require surgery
31
. 
3.2.3   ETIOLOGY 
It is likely that a number of factors contribute to the development of mucosal inflammation. 
Also, variations in influence may account for the clinical diversity seen in UC and CD
32
. 
Although the exact cause of ulcerative colitis remains undetermined, the condition appears to 
be related to a combination of genetic and environmental factors. Whole genome scans have 
found susceptibility genes for UC on chromosomes 1 and 4, although these loci have not been 
uniformly confirmed
33
. 
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Whilst it is unfortunately true to say that the etiology of ulcerative colitis remains obscure, 
during the past few decades many attempts have been made to unravel this complicated 
problem. The most popular theories concerning the etiology of ulcerative colitis can be listed 
as follows. 
Infection 
Even though, ulcerative colitis had clearly been separated from the contagious forms of 
diarrhea by the middle of the nineteenth century, until recently many workers refused to 
believe that this disease was not infectious in nature. Perhaps the most widely celebrated of 
these was Bargen, who in 1924 claimed to have isolated a diplococcus from the stools of 
patients suffering from ulcerative colitis-and even produced a vaccine against this 
diplococcus, which was claimed to be effective in such patients
34
. Unfortunately in the 
fullness of time it became apparent that these claims were not entirely justified. Bargen's 
'diplococcus' was shown to be almost certainly a harmless type of enterococcus found in the 
stools of vast numbers of the general population; and no real convincing evidence was 
forthcoming to suggest that the vaccine was effective in preventing attacks of colitis. 
Since that date other authors have postulated that a number of organisms might be partly 
responsible for ulcerative colitis, including parasites, fungi and various viruses (Fradkin, 
1937
35
: Dragstedt, Dack & Kirsher, 194
36
; Henderson, Pinkerton & Moore, 1942
37
; Victor, 
Kirsner & Palmer, 1950
38
).  
Unfortunately, however, further careful controlled studies have failed to uphold the claims of 
these various organisms to be the offending agents in causing ulcerative colitis. Thus there is 
little concrete evidence nowadays in support of any hypothesis proposing an infectious 
etiology for ulcerative colitis. 
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Mucinases 
In 1947 Meyer and his colleagues proposed that ulcerative colitis might be due to destruction 
of the mucus lining the surface of the colon by enzymes, (which were termed mucinases), 
thus rendering the colon more susceptible to attack by bacterial and other agents. It was 
shown that stool concentration of lysozyme (an enzyme claimed to be capable of digesting 
colonic mucus), was higher in colitic patients than in normal controls, and that the stool 
concentration rose and fell during exacerbations and relapses of colitis
39
. 
It remained; however, far from certain that lysozyme was the cause of this disease; since the 
changes observed in lysozyme titre could very well have been the result instead. Finally this 
hypothesis fell into disrepute when it was shown (albeit in vitro) that lysozyme was incapable 
of dissolving or digesting human mucus
40
. 
 
Allergy 
Despite the fact that some workers have succeeded in producing a type of delayed 
hypersensitivity reaction in the colon of the experimental animal (Rosenberg & Fischer, 
1964; 
Bicks & Rosenberg, 1964), the position of allergens in the etiology of ulcerative colitis is also 
somewhat uncertain at the present time
41
. 
The idea that cow's milk might be in some way responsible for the development of ulcerative 
colitis was first emphasized by Andresen (1925, 1942)
42
. 
More recently as a result of studies by Truelove and his colleagues at Oxford, several 
additional facts have come to light which appear to support this hypothesis. These workers 
have shown that occasional patients with ulcerative colitis experience a remission of their 
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disease when milk products are excluded from their diet, and suffer a relapse when they are 
re-introduced. 
Also it has been shown that the titre of antibodies to milk proteins in the circulation is 
significantly raised in colitic patients when compared with normal matched controls, and it 
has been further suggested that a significantly greater proportion of colitis patients have 
abandoned breast feeding in the 1st month of life than healthy matched controls
41-45
. 
Auto immunity 
The first studies suggesting that ulcerative colitis might be an autoimmune disease are widely 
attributed to Broberger & Perlmann (1959)-although Cornelis (1958) had already suggested 
such a possibility. Broberger & Perlmann (1959), using an extract of foetal colon in tissue 
culture, were able to show haemagglutinating antibodies to the colonic mucosa in no less than 
twenty out of thirty children with ulcerative colitis
46
. 
It was still possible to argue that the changes which Broberger & Perlmann had observed 
were occurring as a totally independent phenomenon, and were unrelated to the disease 
process of ulcerative colitis. But this argument was in part refuted by their further studies 
(Perlmann & Broberger, 1963) showing that the leucocytes from patients with ulcerative 
colitis had a cytotoxic effect upon the foetal colon cells in tissue culture, an effect which was 
inhibited by pre-treatment with colon antigen
47
.However, recent studies by Harrison (1965)
48
 
and by Wright & Truelove (1966) have shown that autoantibody to colon can be 
demonstrated in only 15 or 20% of patients with ulcerative colitis
49
 ; and moreover there is 
little correlation between the clinical course of colitis and the incidence of circulating 
antibodies to colon. 
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Genetic Factors 
Epidemiological and family studies demonstrate that genetic factors play a role in the 
susceptibility to IBD
50
. The disease is, however, genetically complex and cannot be explained 
by a single gene model alone
50
. It is thought that UC and CD may be heterogeneous 
polygenic disorders sharing some but not all susceptibility loci. 
Most likely, the disease phenotype is determined by several factors, including interaction 
between allelic variants at a number of loci, as well as genetic and environmental 
influences
50
. There have been a number of reports of families in which several members have 
inflammatory bowel disease and it seems likely that there is a genetic predisposition to these 
conditions but the magnitude of the risk is uncertain. Binder et a144 reviewed 152 patients 
with ulcerative colitis compared with matched controls of the same social class. In eight 
families a relative was affected compared with only one in the control group. These findings 
have been confirmed in Stockholm
51
. 
Familial and ethnic syndromes  
There is an increased prevalence of IBD in first- and second-degree relatives and a higher 
relative risk among siblings. The familial frequency of IBD ranges from 20% to 30% in 
referral-based studies and between 5% and 10% in population surveys
52
. The higher risk for 
IBD in the Jewish population 53 suggests that genetic factors may play a larger role in some 
subgroups
50
. In families with a high incidence of IBD among first degree relatives, 75% of 
those affected are concordant for either UC or CD, whereas 25% are not concordant, with 
some members having UC and others having CD
52
. This finding indicates that multiple, 
overlapping genetic factors may contribute to disease pathogenesis. Further support for a 
genetic susceptibility comes from the finding of an association between IBD and other 
syndromes with a genetic predisposition
50
. 
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PSYCHOLOGICAL FACTORS 
In 1930, a young medical student, Cecil D. Murray, published a notable paper which claimed 
that psychological factors might be important in the etiology of ulcerative colitis. 
Psychological and physiological evidence has been adduced in favour of this hypothesis. 
Many psychiatrists have observed that a large percentage of patients suffering from ulcerative 
colitis can be induced to confess to 'interhuman conflicts' in the immediate period before an 
attack of the disease (Murray, 1930; Sullivan, 1935; Palmer, 1948; Paulley, 1950, 1956; 
Groen and Van der Valk, 1956)
53
. Further workers, using the Rorschach and other tests, have 
claimed that patients with ulcerative colitis are infantile, dependent, passive, egocentric, 
hesitant, and uncertain. Changes in the attitude to life undoubtedly occur in patients during 
severe attacks of ulcerative colitis. Patients become depressed, morose, and dependent upon 
their clinical attendants. 
Environmental Triggers 
‘‘Westernization’’ 
Ulcerative colitis is most prevalent in developed regions, including the United States, United 
Kingdom, and Scandinavia
26, 27
. The higher incidence of UC seen in industrialized countries 
and the dramatic increase in cases during the 20
th 
century supports the theory that 
environmental factors contribute to disease development
28
. This may also account for the 
north-to-south variation and higher frequency in urban communities compared with rural 
areas. Interestingly, increases in incidence have recently been noted in southern countries and 
Asia and among migrants to first-world countries 
26, 27
. It is postulated that this is the result of 
‗‗westernization‘‘ of lifestyle, such as changes in diet, smoking, and variances in exposure to 
sunlight, pollution, and industrial chemicals
26
. 
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Tobacco smoking 
The strongest environmental risk factor for IBD is tobacco smoking, particularly among 
consumers of cigarettes. The relationship between IBD and smoking is complex, suggesting 
unique pathophysiological factors for both UC and CD. Numerous case-control studies have 
shown that current smoking is protective against UC (relative risk, 40% of that of non-
smokers), with results that are consistent across diverse geographic regions
28
.The decreased 
risk for UC in smokers appears to be dose dependent
54
. Current smoking also is protective 
against sclerosing cholangitis
55, 56
.and pouchitis
57
. Paradoxically, ex-smokers are 
approximately 1.7 times more likely to develop UC than those who never smoked
28
 
Diet 
Studies seeking to link diet and IBD are generally inconclusive. There is some evidence that a 
higher intake of fatty acids increases the risk for IBD
28
. Similarly, Persson et al
58
. Suggests 
that frequent fast-food intake confers a 3- to 4-fold greater risk for IBD. 
3.2.4. Pathophysiology 
Ulcerative colitis is a chronic idiopathic inflammatory disorder of the GI tract. While Crohn's 
disease and ulcerative colitis share a number of gastrointestinal and extraintestinal 
manifestations and can respond to a similar array of drugs, emerging evidence suggests that 
they result from fundamentally distinct pathogenetic mechanisms
59
. Histologically, the 
transmural lesions in Crohn's disease exhibit marked infiltration of lymphocytes and 
macrophages, granuloma formation, and submucosal fibrosis, whereas the superficial lesions 
in ulcerative colitis have lymphocytic and neutrophilic infiltrates. Within the diseased bowel 
in Crohn's disease, the cytokine profile includes increased levels of interleukin-12, interferon-
g, and tumor necrosis factor-a, findings characteristic of T- helper 1-mediated inflammatory 
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processes. In contrast, the inflammatory response in ulcerative colitis resembles more closely 
that mediated by the TH2 pathway. 
The innate immune system is the body‘s nonspecific defense against pathogens; it responds 
immediately or within the first few hours after a challenge. This is commonly considered the 
first line of defense and includes such physical barriers as the skin and the intestinal mucosa 
as well as immune cells that identify and remove foreign bodies. The innate immune system 
reacts to the chemical properties of the antigen rather than to the specific antigen itself. The 
acquired immune system, however, responds specifically to antigens. The antigen is 
processed and recognized, and immune cells that are specific to that antigen are then 
selectively proliferated. Memory is also a part of adaptive immunity, which improves the 
efficiency of future immunologic responses. The traditional view of the pathogenesis of 
inflammatory bowel disease is that intestinal inflammation is mediated by cells of the 
acquired immune system. The chronic inflammation could result from overly aggressive 
activity of effectors lymphocytes and proinflammatory cytokines, which overcome the 
control mechanisms. 
Alternatively, IBD may result from a primary failure of regulatory lymphocytes and 
cytokines, such as interleukin-10 and transforming growth factor to control inflammation and 
effector pathways
60, 61
. In addition, a central pathogenic mechanism in Crohn disease is the 
resistance of T cells to undergoing apoptosis after activation.  
Presentation of intraluminal antigens to mucosal lymphocytes by antigen-presenting cells 
(APCs) leads to the generation of effector responses. In the normal gut (left), overt 
inflammation is prevented by controlling the activation of mucosal effector T cells (Teff) 
through at least 2 distinct mechanisms (Fig.3). First, regulatory T-cell subpopulations (Treg) 
in the mucosal immune system suppress effector T-cell activity in part through the production 
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of interleukin-10 and transforming growth factor. Second, control is also provided by 
eliminating Teff by apoptosis, thereby preventing undesired overexpansion. In individuals 
with IBD, both of these regulatory mechanisms seem to be defective (right). 
          
 
Fig. 3: The traditional paradigm for the pathogenesis of inflammatory bowel disease 
(IBD). 
The exact cause of this phenomenon has not yet been fully elucidated; nonetheless, the ability 
of anti–tumor necrosis factor and anti–interleukin-12 antibodies to efficiently prevent or 
reverse clinical and experimental IBD is largely mediated by their ability to restore mucosal 
homeostasis and redirect mucosal effector T cells into apoptotic pathways. In both scenarios, 
lymphocytes are considered to be the major culprits. However, there is emerging evidence 
that defects in the innate immune system play an equal or even more important role in IBD
62, 
63
. Evidence of the role of the innate immune system comes from the recently discovered 
association between Crohn disease and loss-of-function mutations in the caspase-activating 
and recruitment domain 15 gene (card15 - so named because the protein it encodes contains a 
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CARD protein–protein interaction domain), which is also known as nod2. The NOD2 protein 
is an intracellular receptor for a component of the bacterial cell wall and plays an important 
role in triggering cells of the innate immune system. 
3.2.5   ULCERATIVE COLITIS: MACROSCOPIC FEATURES 
The macroscopic assessment of colectomy specimens remains important despite the 
widespread use of colonoscopy and endoscopic biopsy in IBD diagnosis. A careful and 
thorough description, ideally with gross photographs, can be critical in assigning the correct 
diagnosis. Factors that are particularly important to note are: 
 The distribution of colitis. 
 Appearance of ulcers and intervening mucosa, and 
 The appearance of the colonic wall. 
Ulcerative colitis begins in the rectum and extends proximally. Disease confined to the 
rectum and associated with prominent lymphoid follicles has been regarded as a separate 
disorder by some (follicular proctitis
64
) based on reduced responsiveness to therapy. Apparent 
rectal sparing can occur due to prior topical steroid therapy and skip lesions in the appendix 
and cecum are allowable. Crohn‘s disease can affect any part of the Inflammatory Bowel 
Disease colon and may produce a pan colitis, but the ascending colon and rectum are the 
most common colonic sites. 
In colectomy,  performed for severe UC the ulcers can have several forms. Typically, broad 
and flat areas of ulceration due to mucosal undermining and loss are seen between obviously 
inflamed, hyperaemic and granular mucosa, often with pseudo polyp formation. Intermittent 
ulceration can occur giving the impression of skip areas
65
 and in these cases histology is 
necessary to confirm milder colitis (rather than normal mucosa) between the ulcerated areas. 
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The second type of ulceration seen in severe UC is linear, occurring where the plicae 
semilunares converge along the lines of attachment of the three taeniae coli. This should not 
be confused with the fissuring ulceration of CD. Finally, fine fissuring into submucosa occurs 
in toxic dilatation, although this is better appreciated microscopically. The ulcers of CD, on 
the other hand, vary from small aphthous ulcers aligned longitudinally and surrounded by 
normal mucosa to deep and narrow, fissuring ulcers separating mounds of normal appearing 
mucosa. This latter appearance is termed cobble-stoning. In the ileum, fissuring is most 
prominent on the mesenteric side of the bowel wall compared with the antimesenteric 
location in ischaemic enteritis. 
The colonic wall is not significantly thickened in UC. There may be some shortening and 
simplification of the haustral pattern due to fibrosis in the mucosa and upper submucosa as a 
result of repeated flares. Although generally a mucosal disease, UC can show 
limitedtransmural inflammation in areas of severe ulceration, resulting in serosal hyperemia. 
This occurs in the absence of wall thickening or fat creeping. 
In CD the colonic wall is typically thickened due to edema, fibrosis and smooth muscle 
proliferation. This thickening and structuring is sometimes so severe as to suggest 
malignancy macroscopically. The serosal fat is increased and wraps around the intestinal 
wall. Some authors have advocated the separation of Crohn‘s disease into perforating and 
non-perforating types on the basis of perceived differences in clinical aggressiveness and 
complications but this subdivision remains clinically controversial
66
. 
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Fig 4: Pan-ulcerative colitis  
Mucosa has a lumpy, bumpy appearance because of areas of inflamed but intact mucosa 
separated by ulcerated areas. 
3.2.6     ULCERATIVE COLITIS: MICROSCOPIC FEATURES 
Normal mucosa   
Before discussing the salient microscopic features of inflammatory bowel disease, it is 
necessary to outline the normal appearances of mucosa and submucosa. The crypts within the 
mucosa are of uniform length, diameter and spacing giving an appearance that has been 
likened to test tubes in a rack. The crypts should reach the muscularis mucosa in all areas of 
the colon except the rectum, where it is normal to have uniform mild shortening. In the region 
just above the anorectal junction, significant crypt distortion is common and this area is 
generally avoided at biopsy. The crypt density is 7-8 per mm except in areas of lymphoid 
follicle formation where the density reduces significantly. Branched crypts can be seen in 
normal biopsies but should not exceed 10% of all crypts; from a practical point of view more 
than two branched crypts in a biopsy is excessive
67
.  
The lamina propria contains a mixed inflammatory infiltrate in which lymphocytes and 
plasma cells predominate, neutrophils are particularly rare and eosinophils may be present in 
variable numbers. Inflammatory cells are generally more numerous in the superficial lamina 
propria. Lymphoid aggregates can be present in the mucosa and upper submucosa, 
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particularly in the rectum, and they may cause the mucosa to bulge slightly. Macrophages 
containing mucin (muciphages) are commonly seen in normal rectal biopsies, and are 
increased nonspecifically following mucosal injury. The normal submucosa is composed of 
loose fibrovascular connective tissue. The thickness is not uniform, and areas of relative 
thinning occur where the mucosa almost touches the muscularis propria. If this area becomes 
inflamed it may be misinterpreted as fissuring ulceration
67
.  
Idiopathic IBD is generally diagnosed in the presence of abnormal mucosal architecture with 
or without superimposed inflammation in the lamina propria. The guidelines outlined by the 
British Society of Gastroenterology are currently the favoured ones for histological diagnosis. 
The typical mucosal architectural changes develop several weeks after the onset of the first 
attack of colitis so that biopsies taken very early in the course, or in children
68
, may not be 
diagnostic. Architectural changes take about 15 days to develop but the basal 
lymphoplasmacytosis occurs earlier. There is a variable degree of crypt shortening; reduced 
crypt density, variable crypt diameter and crypt branching that can be subtle, particularly in 
quiescent colitis.  
The pattern of mucosal inflammation is often distinctive in active IBD. In many cases the 
inflammatory infiltrate is predominantly composed of lymphocytes and plasma cells 
distributed throughout the lamina propria, often with a prominent basal lymphoplasmacytosis. 
Neutrophils are also prominent and are associated with cryptitis and crypt abscess formation. 
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Fig .5:   Characteristic findings of IBD in a case of ulcerative colitis: crypt distortion, 
cryptitis and crypt abscess. 
 
Rupture of large crypt abscesses with undermining of the adjacent mucosa may be seen, or 
large abscesses can rupture into the upper submucosa. Non-caseating epithelioid granuloma 
can be seen in some but not all cases of CD, but it must be remembered that a granulomatous 
reaction is relatively common around ruptured crypts in UC and this patternis not diagnostic 
of CD. 
Because of the size and nature of mucosal biopsies, fissuring ulceration and transmural 
inflammation cannot be diagnosed reliably from usual-sized biopsies, but fissuring may be 
suspected if granulation tissue is seen running down one side of a biopsy which has relatively 
unremarkable mucosa at the other end. 
3.3   TREATMENT 
AMINOSALICYLATES 
Aminosalicylates can be used in combination with steroids to induce and maintain remission 
in patients with inflammatory bowel disease. The first-line therapy for mild to moderate UC 
generally involves mesalamine (5-aminosalicylic acid, or 5-ASA). The archetype for this 
class of medications is sulfasalazine, which consists of 5-ASA linked to sulfapyridine by an 
azo bond. Although this drug was originally developed as a treatment for rheumatoid 
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arthritis, clinical trials serendipitously demonstrated a beneficial effect on the gastrointestinal 
symptoms of subjects with concomitant UC. 
Sulfasalazine is most effective at maintaining remission in UC. When it reaches the colon, the 
diazo bond is cleaved by bacterial azoreductase, liberating mesalamine and sulfapyridine. 
Sulfapyridine is absorbed and metabolized by hepatic acetylation or hydroxylation followed 
by glucuronidation. Given individually, either 5-ASA or sulfapyridine is absorbed in the 
upper gastrointestinal tract; the azo linkage in sulfasalazine prevents its absorption in the 
stomach and small intestine, and the individual components are not liberated for absorption 
until colonic bacteria cleave the bond. 5-ASA is the active therapeutic moiety; sulfapyridine 
contributes little to the therapeutic effect.  
Although mesalamine is a salicylate, its therapeutic effect does not appear to be related to 
cyclooxygenase inhibition; indeed, traditional nonsteroidal anti-inflammatory drugs may 
actually exacerbate IBD. Many potential sites of action have been demonstrated in vitro for 
either sulfasalazine or mesalamine, including inhibition of IL-1 and TNF- α production, 
inhibition of the lipooxygenase pathway, the scavenging of free radicals and oxidants, and 
inhibition of NF- ḳB (nuclear factor kappa B), a transcription factor pivotal to the production 
of inflammatory mediators
69
. 
Although it is not active therapeutically, sulfapyridine causes many of the same side effects 
observed in patients taking sulfasalazine. To preserve the therapeutic effect of 5-ASA without 
the side effects of sulfapyridine, several second-generation 5-ASA compounds have been 
developed. They are divided into two groups: prodrugs and coated drugs. Prodrugs contain 
the same azo bond as sulfasalazine but replace the linked sulfapyridine with either another 5-
ASA (olsalazine) or an inert compound (balsalazide).  
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These compounds act at similar sites along the gastrointestinal tract as sulfasalazine. The 
alternative approaches employ either a delayed-release formulation or a pH-sensitive coating. 
Delayed-release mesalamine is released throughout the small intestine and colon, whereas 
pH-sensitive mesalamine is released in the terminal ileum and colon. The different 
distributions of these drugs following delivery have potential therapeutic implications. 
 
                            
Fig 6: Structures of sulfasalazine and related agents. 
 
Oral sulfasalazine is of proven value in patients with mild or moderately active ulcerative 
colitis, with response rates in the range of 60% to 80%
70
. The usual dose is 4 g/day in four 
divided doses with food; to avoid adverse effects, the dose is increased gradually from an 
initial dose of 500 mg twice a day. High doses as 6 g/day can be used but that can cause an 
increased incidence of side effects. 
Topical preparations of mesalamine suspended in a wax matrix suppository (ROWASA) or in 
a suspension enema (CANASA) are effective in active proctitis and distal ulcerative colitis, 
respectively
71
.They appear to be superior to topical hydrocortisone in this setting, with 
response rates of 75% to 90%. Mesalamine enemas (4 g/60 ml) should be used at bedtime 
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and retained for at least 8 hours; the suppository (500 mg) should be used two to three times a 
day with the objective of retaining it for at least 3 hours.  
 
Fig 7: Metabolic fates of the different oral formulations of mesalamine (5-ASA). 
 
GLUCOCORTICOIDS 
The glucocorticoid properties of hydrocortisone and prednisolone are the mainstay of IBD 
treatment. The preferred steroid is prednisolone, administered orally, rectally or parenterally 
in emergency situations. Corticosteroids can be used either alone or in combination with a 
suitable mesalamine formulation to induce and maintain remission in inflammatory bowel 
disease. The incidence of adverse effects appears to increase when prednisolone doses are 
higher than 40 mg/day. An alternate-day regimen is helpful because it reduces adrenal 
suppression. Azathioprine is a purine analogue that competitively inhibits the biosynthesis of 
purine nucleotides. Its mode of action is not well understood. Once absorbed azathioprine is 
almost entirely metabolized to 6-mercaptopurine
72
. 
Initial dose for prednisone is between 40 to 60 mg per day; higher doses are rarely more 
effective
73
. In severely ill hospitalized patients, 100 mg of hydrocortisone administered 
intravenously every eight hours is a reasonable initial therapy. Intravenous therapy generally 
produces a rapid improvement of symptoms, with maximal benefits occurring when the 
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corticosteroid has been administered for six to eight days. Once the patient‘s symptoms have 
improved, prednisone is tapered by 5 to 10 mg per week, until the dosage reaches 15 to 20 
mg per day. This dosage is then tapered by 2.5 to 5 mg per week until the drug is 
discontinued. The goal is to remove patients from corticosteroids within a relatively short 
period of time while maintaining disease remission. Concomitant use of 5-ASA agents can be 
helpful. Alternatively, long-term, alternate-day corticosteroid therapy can be used in patients 
with refractory CD, although it may be necessary to use dosages of 20 to 25 mg every other 
day
74
. 
Budesonide is an enteric-release form of a synthetic steroid that is used for ileocecal CD
75
. It 
is thought to deliver adequate steroid therapy to a specific portion of the inflamed gut while 
minimizing systemic side effects caused by extensive first-pass hepatic metabolism to 
inactive derivatives. Topical therapies (e.g., enemas and suppositories) are also effective in 
treating colitis that is limited to the left side of the colon. Budesonide (9 mg/day for 10 to 12 
weeks) is effective in the acute management of mild-to moderate exacerbations of CD, but its 
role in maintaining remission has not been fully determined
76.
 
Hydrocortisone also can be given once or twice daily as a 10% foam suspension that delivers 
80 mg hydrocortisone per application; this formulation can be useful in patients with very 
short areas of distal proctitis and difficulty retaining fluids.  
IMMUNOSUPPRESSANTS 
Several drugs initially developed for cancer chemotherapy or as immunosuppressive agents 
in organ transplants have been adapted for the treatment of IBD. Immunosuppressant drugs 
can be an invaluable adjunct therapy for the treatment of patients with intractable 
inflammatory bowel disease or complex, inoperable perianal disease. Although 
immunosuppressant agents have significant side effects, they are safer and better tolerated 
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than long-term corticosteroid therapy. Before immunosuppressant therapy is initiated, side 
effects and other treatment alternatives should be discussed with the patient. At this stage, it 
is best to set a definable goal, uch as closure of a fistula or tapering the patient off of 
corticosteroids, and a minimum three-month time frame should be set to reach that goal
72
. 
Since the early 1970s, azathioprine and mercaptopurine have been used to treat IBD. These 
drugs are superior to the placebo, but their full effects may not become apparent for as long 
as three months. Azathioprine and mercaptopurine are beneficial in 50 to 70% of patients 
with intractable perianal CD
77
. 
The cytotoxic thiopurine derivatives mercaptopurine (6-MP) and azathioprine are used to 
treat patients with severe IBD or those who are steroid-resistant or steroid-dependent
78
. 
Both are prodrugs; azathioprine is converted to mercaptopurine, which is subsequently 
metabolized to 6-thioguanine nucleotides, typically, azathioprine is administered at a dose of 
2 to 2.5 mg/kg and mercaptopurine is given at a dose of 1.5 mg/kg. Because of concerns of 
side effects, these drugs were used initially only in CD. 
For both azathioprine and mercaptopurine, the initial dosage is 50 mg per day. A therapeutic 
benefit usually occurs at dosages of 50 to 100 mg per day for mercaptopurine and 75 to 150 
mg per day for azathioprine.  
Mild leukopenia suggests that the drug is effective and therefore more likely to benefit the 
patient. It is prudent to obtain a complete blood count every two weeks during the initial 
treatment phase in patients with active disease and every three months in patients on 
maintenance therapy
79
. 
Chapter 3                                                                         REVIEW OF LITERATURE 
 
Dept. of Pharmacology, Padmavathi College of Pharmacy  Page 33 
 
For more than 20 years, low-dose methotrexate therapy has been used in patients with 
intractable psoriasis and rheumatoid arthritis. Methotrexate was engineered to inhibit 
dihydrofolate reductase, thereby blocking DNA synthesis and causing cell death. First 
used in cancer treatment, methotrexate was subsequently recognized to have beneficial 
effects in autoimmune diseases such as rheumatoid arthritis and psoriasis. The anti-
inflammatory effects of methotrexate may involve mechanisms in addition to its 
inhibition of dihydrofolate reductase. One study showed that this treatment was beneficial 
in 70% of patients with severe IBD80. 
CYCLOSPORINE 
The calcineurin inhibitor cyclosporine is a potent immunosuppressant drug used in organ 
transplantation. Since the mid-1980s, this drug has also been used to treat patients with IBD. 
At this time, cyclosporine is most useful in severely ill patients with UC who have not 
responded to corticosteroid therapy. In such patients, intravenously administered 
cyclosporine is highly effective for rapid disease control, and it may allow patients to avoid 
surgery. However, after one year, 70 to 80% of these patients may still require surgery. Thus, 
in many patients, the role of cyclosporine is to change a risky emergency operation into a less 
urgent procedure
81
. 
Cyclosporine is effective in severe UC that has failed to respond adequately to glucocorticoid 
therapy. Between 50 and 80% of these severely ill patients improve significantly (generally 
within 7 days) in response to intravenous cyclosporine (2 to 4 mg/kg daily), which sometimes 
allows them to avoid an emergent colectomy. 
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3.4     Different Animal Models 
 
ACETIC ACID INDUCED ULCERATIVE COLITIS IN RATS: 
 
The experiment was performed using acetic acid for inducing colitis
82
. All the animals will be 
pre-treated with the respective drugs for 8 days along with the normal diet.  On the 4th day of 
the treatment, the animals will be fasted overnight with access to glucose containing water ad 
libitum. On the 5
th
 day after 1 h of the aforementioned treatments, the animals (Groups II to 
V) will be anesthetized by ether inhalation and a polypropylene tube with 2 mm diameter will 
be inserted through the rectum into the colon to a distance of 8 cm. Initially, each rat received 
a 1 ml saline (0.9%) flush followed by manual palpation of the abdomen to remove any feces. 
Then, a solution of 2 ml of acetic acid (3%, v/v) in 0.9% saline will be  instilled into the 
lumen of the colon and maintained in a supine Trendelenburg position for 30 s to prevent the 
leakage of the intracolonic instillate.  After 72 h of single dose administration of acetic acid 
(on 8
th
 day), clinical activity scores will be measured and the animals will be anaesthetized 
with ether and blood will be collected by retro orbital puncture for biochemical estimation. 
The animals will be sacrificed by cervical dislocation and colon will be dissected out. Colon 
will be flushed gently with saline and weighed. It is used for macroscopic scoring, 
histopathological and biochemical estimations
83
. 
In the intestinal tract, energy status is a fundamental regulator of epithelial cell metabolism
84
. 
An energy deficit has been considered to be a pathogenic factor in ulcerative colitis, which is 
substantiated by the fact that the intestinal mucosa has a limited capacity for-denovo 
synthesis of purine nucleotides
85
, and is more prone to reduced ATP concentrations compared 
with the liver or muscle
86
. 
On the other hand, IL-6 and tumor necrosis factor α (TNF-α) has been shown to play an 
important role in the pathogenesis of inflammatory bowel disease
87
. These pro-inflammatory 
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cytokines drive the activation and recruitment of inflammatory cells, amplify the production 
of other pro-inflammatory cytokines, and activate nuclear transcription factors, thereby 
promoting and maintaining the inflammatory response
88
. Additionally, release of 
transforming growth factor- α (TGF-α) and expression of TGF- α mRNA are increased after 
acute gastric injury and in the colonic mucosa from patients with IBD
89, 90
. 
DSS induced colitis 
For the induction of colitis, mice were administered 3% (w/v) DSS dissolved in drinking 
water for various time periods. One cycle consisted of 7 days of DSS treated water followed 
by 14 days of normal drinking water. Animals were divided into various groups, each group 
consisting of 8 animals; and mild, moderate and severe colitis were induced in them. Group 1 
received normal drinking water and served as control. Group 2 (mild colitis) received DSS 
(3%, w/v) for 7 days and the animals were sacrificed on the 8th day. Group 3 (moderate 
colitis) received DSS (3%, w/v) from days 1 to 7 and 22 to 28 and the animals were 
sacrificed on the 29th day. During the remission period (days 8–21) mice were administered 
normal drinking water. Similarly, group 4 (severe colitis) received DSS (3%, w/v) from days 
1 to 7, 22 to 28 and 43 to 49 and the animals were sacrificed on the 50th day. During the 
remission period (days 8–21 and 29–42) mice were administered normal drinking water. To 
assess the extent of colitis, weight loss, stool consistency and rectal bleeding were monitored 
daily in order to calculate the disease activity index (DAI). DAI is referred to as the average 
combined score of weight loss (0–4), stool consistency (0–4) and rectal bleeding (0–4) used 
to score clinical symptoms
91
. 
Feeding mice for several days with DSS polymers in the drinking water induces a very 
reproducible acute colitis characterized by bloody diarrhea, ulcerations and infiltrations with 
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granulocytes. It is believed that DSS is directly toxic to gut epithelial cells of the basal crypts 
and therefore affects the integrity of the mucosal barrier. 
As T- and B-cell deficient mice also develop severe colitis, the adaptive immune system 
obviously does not play a major part in this model . Hence, the acute DSS colitis model is 
particularly useful to study the contribution of innate immune mechanisms of colitis. In 
addition, the DSS model has been shown to be suitable to study epithelial repair mechanisms. 
Studies with TLR4−/− and MyD88−/− mice suggest that TLR signaling is required to limit 
bacterial translocation after DSS induced intestinal epithelial injury suggesting that TLR 
signaling is important for the maintenance of the epithelial barrier . In susceptible strains, the 
administration of DSS for several cycles (e.g., 7 days DSS, 14 days water) results in chronic 
colitis and if combined with a single initial dose of the genotoxic colon carcinogen 
azoxymethane (AOM), in inflammation-associated colorectal cancer. Patients with UC have 
an increased risk for the development of colon cancer. As colonic inflammation is suggested 
to play a key role in IBD-related colorectal cancer, the AOM/DSS model is a very useful tool 
to study mechanisms linking inflammation to colon carcinogenesis. 
TNBS induced colitis 
Colitis can be induced in susceptible mouse strains by intrarectal instillation of the 
haptenating substances TNBS/ DNBS or Oxazolone dissolved in ethanol with or without a 
skin presensitation step. Ethanol is required to break the mucosal barrier, whereas 
TNBS/Oxazolone is believed to haptenize colonic autologous or microbiota proteins 
rendering them immunogenic to the host immune system. As CD4+ Tcells have been shown 
to play a central role in chronic TNBS colitis, this model is useful to study T helper cell-
dependent mucosal immune responses. The TNBS colitis model has been very useful in 
studying many important aspects of gut inflammation, including cytokine secretion patterns, 
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mechanisms of oral tolerance, cell adhesion and immunotherapy. Murine TNBS colitis has 
been initially described in SJL/J mice, a mouse strain with high susceptibility that develops 
chronic TNBS colitis characterized by a predominant TH1-mediated immune response with 
dense infiltrations of lymphocytes/macrophages and thickening of the colon wall . However, 
studies with IFN-γ−/− mice on a Balb/c background showed that in these mice TNBS colitis 
may be associated with a TH2-mediated colonic patch hypertrophy. In SJL/J mice, 
Oxazolone colitis has been shown to affect only the distal colon and particularly mucosal 
layers.  
Histological features and an elevated production of TH2 cytokines (IL-4, IL-5 and IL-13) of 
unstimulated and αCD3/αCD28-stimulated lamina propria T cells are in these mice, in some 
aspects, similar to characteristics that have been observed in human UC. In contrast to several 
other murine colitis models, treatment with neutralizing anti-IL-4 antibodies or a decoy IL-
13Rα2-Fc protein ameliorates disease. This group has shown that Oxazolone colitis depends 
on the presence of IL- 13 producing invariant natural killer (NK) T cells. Consistently, mice 
deficient for Epstein Barr virus induced gene 3 (EBI3) that have a defect in iNKT cell 
generation, are resistant to Oxazolone colitis. Thus Oxazolone colitis is one of the few 
models suitable to study the contribution of the TH2-dependent immune response to intestinal 
inflammation. As in the TNBS model, oxazolone colitis is strain dependent and requires 
individual optimization. This is exemplified by the fact that oxazolone at lower doses can 
induce a mixed TH1/TH2-dependent colitis
92
. 
Indomethacin-induced colitis in rats 
The experiment was performed using indomethacin. Normal or untreated animals which did 
not receive any treatment; Control animals received only indomethacin (7.5 mg/kg, s.c.), on 
two consecutive days; Drug treated animals received 7 days pre-treatment with polyherbal 
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formulation and indomethacin (7.5 mg/kg, s.c.) on 8th and 9th day. Drug treatment was 
continued till 11th day; Prednisolone treated group, which received prednisolone (2 mg/kg, 
p.o., for 4 days) and indomethacin (7.5 mg/kg, s.c., for 2 days). Prednisolone and 
indomethacin treatment was started on the same day. Rats of either sex (200–250 g) were 
given indomethacin 7.5 mg/kg subcutaneously on two consecutive days. On the fourth day 
animals were sacrificed by cervical dislocation and dissected open to remove GIT (from 
stomach to anus). GIT was flushed gently with saline and cut open. Cecum, 10 cm long 
pieces of ileum and colon were scored for inflammation based on their macroscopic features. 
Tissues were fixed in 10% formalin saline and examined histopathologically. Quantification 
of inflammation was done using myeloperoxidase assay. 
Iodoacetamide-induced colitis 
This model, initially described by Satoh, Sato, Takami and Szabo, is based on the fact that 
endogenous sulfhydryl (SH) compounds, such as glutathione, play an important role in the 
protection of gastric mucosa. Instillation of SH blocker in the colon could induce colitis and 
cause injury to the mucosa by decreasing the amount of defensive SH compounds. After the 
induction of UC, many changes characteristic of inflammation were taken into account to 
determine the degree or severity of the disease related to the administered doses of 
iodoacetamide. The different alterations included diarrhea, dilatation, adhesion, mucosal 
damage (varying from slight mucosal erosion to deep lesion), and inhibition of body weight 
gain. 
 
Heparin, a polyanionic highly sulfated linear polysaccharaide, belonging to the family of 
glycosaminoglycans, has been implicated in the management of UC. Heparin therapy resulted 
in significant improvement in macroscopic and microscopic features of colitis, accompanied 
by a partial reduction in myeloperoxidase (MPO) levels.  
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The regular trends in the behavior of colonic fibroblast growth factor (FGF)- binding activity 
and HB–epidermal growth factor (EGF)-binding activity levels were reversed with heparin 
therapy. However, conflicting studies and results have been published on the response to 
heparin in patients with severe UC since it was first reported. The investigators concluded 
that one mechanism of heparin-mediated improvement in colitis may involve tissue healing 
associated with changes in functional levels of colonic growth factors. On the other hand, 
using the same model, it was shown that anti-surfactant-like particles antibodies ameliorated 
the inflammation in IBD. 
Oxazolone colitis:  
Boirivant, Fuss, Chu, and Strober reported that an enema of oxazolone with ethanol would 
induce colitis. In comparison with TNBS, this agent caused colitis earlier. The peak of body 
weight loss and diarrhea was seen on the second day after the enema, and symptoms 
diminished after 10–12 days. Colitis, accompanied by ulcers, was localized in the distal 
colon. Histopathological studies showed that the numbers of epithelial cells, goblet cells, and 
glands have decreased compared with controls. In contrast to TNBS colitis, these findings 
closely resembled those of UC. 
Peptidoglycan–polysaccharide (PG–PS) colitis 
In 1988, Sartor, Bond, and Schwab demonstrated that the intramural injection of the bacterial 
cell wall component PG–PS into the distal colon of rats induced transmural enterocolitis. In 
genetically susceptible Lewis rats, chronic granulomatous colitis developed 3–4 weeks after 
injection. Histopathologically, there were thickening of the colon wall, infiltration of 
lymphocytes, macrophages, and neutrophils. PG–PS increased mucosal permeability and 
MPO activity, and enhanced NO production and collagen synthesis. Data obtained from this 
model clearly showed that the cell wall components of non-pathogenic resident enteric 
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bacteria are sufficient to induce acute and chronic colitis in a susceptible host when they 
penetrate the colon wall
93
. 
 
3.5     PLANT LITERATURE 
 
3.7.1   Detail of plant is given below: 
 
Name of the plant: Punica granatum Linn. 
Family: Punicaceae. 
Habitat: Native to Iran; but cultivated throughout India. 
Vernacular Names: 
English - Pomegranate. 
Ayurvedic - Daadima, Daadimba, Raktapushpa, Dantabijaa, Raktakusumaa, Lohitpushpaka. 
Unani -   Anaar, Roomaan, Gulnaar,Gulnaar Farsi 
Siddha/Tamil - Maathulai. 
Hindi: Anar 
Unani -   Anaar, Roomaan, Gulnaar,Gulnaar Farsi. 
Marathi: Dalimb 
Manipuri: Kamphoi 
3.7.2   Plant description: 
Order: Myrtales 
Kingdom: Plantae 
The pomegranate is an ancient fruit that has not changed much throughout the history of man. 
It was found in the Indus Valley so early that there is a word in Sanskrit for pomegranate. 
The pomegranate is also significant in Jewish, Christian and Muslim traditions. The 
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pomegranate is native of Iran and Afghanistan, known in ancient Egypt. This includes only 
two species. More than 500 cultivars of Punica granatum exist with specific Characteristics 
such as fruit size, exocarp and aril color, etc. Originating from the Middle East, pomegranate 
is now widely cultivated throughout the world, and also widely consumed. Pomegranate has 
been used for centuries in the folk medicine of many cultures
94
. 
 
Fig 8: Photograph of plant Punica granatum Linn 
 
 
 Fruits:  is a berry of 5 to 12 cm diameter with a leathery, deep red peel (husk, rind, 
and pericarp are synonyms). The fruit‘s interior is separated by membranous walls 
into compartments containing arils filled with pulp. Each aril contains one angular 
seed. Phenolic Compounds are present in different parts of pomegranate plants; they 
are found in seeds, arils, fruit peels, leaves, flowers, tree bark, and roots
94
. 
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Fig 9: Photographs showing fruits of Punica granatum Linn. 
 Leaves: leaves are opposite or sub opposite, glossy, narrow oblong, entire, 3-7 cm 
long and 2 cm broad
94
. 
                               
Fig 10: Photograph showing leaves of Punica granatum Linn. 
 Seeds: Each seed has a surrounding water-laden pulp-the edible aril-ranging in colour 
from white to deep red. The seeds are embedded in a white, spongy pulp. 
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Fig 11: Photograph showing seeds of Punica granatum Linn. 
 Flowers: are bright red, 3 cm in dm, with 4 or 5 petals. 
 
Fig 12: Photographs showing flowers of Punica granatum Linn. 
Chemical constituents: 
Pomegranate Juice -  anthocyanins, glucose, ascorbic acid, ellagic acid, Gallic acid; caffeic 
acid; catechin, EGCG, quercetin, rutin; numerous minerals, particularly iron; amino acids. 
Pomegranate seed oil - 95-percent punicic acid; other constituents, including ellagicacid; 
other fatty acids; sterols. 
Pomegranate pericarp (Peel, rind) - Phenolic punicalagins; gallic acid and other fatty acids; 
catechin, EGCG; quercetin, rutin and other flavonols; flavones, flavonones; anthocyanidins. 
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Pomegranate leaves - Tannins (punicalin and punicafolin); and flavones glycosides, 
including luteolin and apgeni. 
Pomegranate flower - Gallic acid, ursolic acid; triterpenoids, including maslinic and Asiatic 
acid; other unidentified constituents 
Pomegranate roots and bark - Ellagitannins, including punicalin and punicalagin; 
numerous piperidine alkaloids. 
Table 1: Plant component and its constituents 
 
Plant component 
 
Constituents 
Pomegranate juice Anthocyanins, glucose, ascorbic acid, gallic acid, caffeic 
acid, catechin, rutin, amino acids. 
Pomegranate seed oil Purinic acid, ellagic acid, sterols, fatty acids. 
Pomegranate peel Gallic acid, catchin, quercetin, rutin, flavonoids. 
Pomegranate leaves Tannins, flavones glycosides. 
Pomegranate flower Gallic acid, ursolic acid, triterpenoids, asiatic acid 
Pomegranate roots Ellagitannins, piperidine alkaloids. 
 
The major class of pomegranate phytochemical is polyphenols that predominate in 
fruits
95
.Pomegranate polyphenols include flavonoids condensed tannins and hydrolysable 
tannins. Hydrolysable tannins (HTs) are found in the peels (rind, husk, or pericarp), 
membranes and piths of the fruit. HTs are predominant polyphenols found in pomegranate 
juice and account for 92% of its antioxidant activity
96
. 
The presence of phytoconstituents make the plant useful for treating different ailments and 
have a potential of providing useful drugs of human use. In the present study, we have found 
that most of the biologically active phytochemicals were present in the ethanolic, aqueous 
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and chloroform extracts of Punica granatum peel, whole fruit and seeds. The medicinal 
properties of Punica granatum peel, whole fruit and seeds extract may be due to the presence 
of above mentioned phytochemicals. 
3.7.3   Medicinal Uses: 
Bark and the roots are believed to have anthelmintic and vermifuge properties; the fruit peel 
has been used as a cure for diarrhea, oral aphthae, and as a powerful astringent, the juice as a 
blood tonic, and the flowers as a cure for diabetes mellitus
94
. Consumption of polyphenoles 
and flavonoids is beneficial for the prevention of cardiovascular, inflammatory and other 
diseases
96
. Rind of fruit is astringent, stomachic, digestive. Used for diarrhea, dysentery, 
colitis, dyspepsia and uterine disorders. Leaf is used in stomatitis .Fresh juice of fruit is 
refrigerant, antiemetic; given as An adjuvant in diarrhea, dyspepsia, biliousness, 
inflammations of the stomach, palpitation, excessive thirst and fevers
97
. Bark of stem and 
root—anthelmintic, febrifuge, given for night sweats. Rind of fruit, bark of stems and root is 
antidiarrhoeal. Powdered flower buds are used in bronchitis
20
. 
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MATERIALS AND METHODS 
 
4.1 Materials 
4.1.1 Collection and authentication of plant material: 
The fresh peels of Punica Granatum used for the present studies were collected from 
Kariapatti, Salem in April 2017. It was authenticated by A.Balasubramaniyam, Executive 
Director, ABS Botanical Garden, Salem. The dried peels were pulverized separately into 
coarse powder by a mechanical grinder and were used for extraction. 
Methods:- 
4.2   Preparation of Hydro Alcoholic Extract: 
The powdered material was subjected to hydro-alcoholic extraction in Soxhlet apparatus by 
using water and ethanol as solvents. The powdered material (150 gm) of P. granatum peels 
were packed in Soxhlet extractor and extracted using solvents for 15hrs successive cycles. 
The temperature was maintained on an electric heating mantle with thermostat control. 
Appearance of colorless solvent in the siphon tube was taken as the termination of extraction. 
The extract was concentrated by using rotary flash evaporator. The concentrated extract was 
then air dried at room temperature, weighed and percentage yield was calculated. The color 
and consistency of the extract were noted. 
  
Chapter 4                                                                                   MATERIALS AND METHODS 
 
Dept. of Pharmacology,Padmavathi College of Pharmacy Page 47 
 
4.3 Preliminary Qualitative Phytochemical Analysis:
 98, 99
 
The following tests were carried out on the herbal extract to detect various phytoconstituents. 
A. Test for Alkaloids: 
0.5 gm extract was dissolved in 10 ml of dilute hydrochloric acid and filtered. The filtrate 
was used to test the presence of alkaloids: 
I. Mayer’s test 
To one ml of filtrate, 2 ml of Mayer’s reagent was added in a test tube. Formation 
ofYellow cream precipitate indicates the presence of alkaloids. 
II. Wagner’s test 
One ml of filtrate was treated with few drops of Wagner’s reagent.  Formation of 
reddish brown precipitate indicates the presence of alkaloids. 
III. Dragendorff’s  test   
One ml of filtrate was treated with few drops of Dragendorff’s reagent.  Formation of  
reddish  brown  precipitate  indicates  the presence ofalkaloids. 
IV. Hager’s test:   
One ml of filtrate was treated with few drops of Hager’s reagent. Formation of 
yellow precipitate indicates the presence of alkaloids. 
B. Tests  For Glycosides 
I. Bromine water test:  
Test extract was dissolved in bromine water. Formation of yellow precipitate indicates 
the presence of glycosides. 
II. Baljet  test:   
Test extract was treated with sodium pirate.Formation of yellow to orange 
colourindicates the presence ofglycosides. 
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III. Keller-Killiani  test:  
0.5g of dried extract was dissolved in 2 ml of glacial acetic acid containing one drop 
of ferric chloride solutions. This was then under laid with 1 ml of concentrated 
H2SO4. It forms two layers, lower layer reddish brown and upper acetic acid layer 
turns bluish green, indicates the presence ofglycosides. 
IV. Legal’s test:   
Test extract was treated with pyridine (made alkaline by adding sodium nitroprusside 
solution).Formation of pink to red colour indicates the presence ofglycosides. 
C. Tests  ForTannins 
I. Ferric chloride test:  
Few drops of 5% w/v FeCl3 solution was added to 1-2ml of the extract.Formation 
of brown colour indicates the Presence of pseudo tannins. 
II. Vanillin  hydrochloride test: 
Extract was treated with vanillin hydrochloride reagent. Formation of purplish red 
colour indicates the Presence of tannins. 
III. Gelatin test:  
Extract was treated with gelatin solution.Formation of white precipitate indicates 
the Presence of tannins. 
 
D. Tests  For Saponins 
I. Sulphur  test:   
Sulphur was added to the extract solution.Sulphur sinks at bottom indicates the 
Presence ofsaponins. 
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II. Froth’s  test: 
 The extract was diluted with distilled water and shaken for 15 min.Formation 
of foamindicates the Presence ofsaponins. 
III. Liebermann Buchard’s test:  
The extract was treated with chloroform and filtered.  The filtrates were 
treated with few drops of acetic anhydride boiled and cooled. Concentrated 
sulphuric acid was added through the sides of the test tube. The formation of 
brown ring at the junction indicated the presence of steroidal saponins. 
E. Tests  For Carbohydrates 
Extracts were dissolved individually in 5ml of distilled water and filtered. The 
filtrates were used to test the presence of carbohydrates. 
I. Molisch’s Test:  
Filtrates  were  treated  with  2  drops  of  alcoholic  α-naphthol  solution  in  a  
test tube  and  2  ml concentrated sulphuric acid was added carefully along the 
sides of the test tubes. Formation of violet ring at the junction indicates the 
presence of carbohydrates. 
II. Benedict’s Test: 
Filtrates  were  treated  with  Benedict’s  reagent  and  heated  on  water  bath.  
Formation of an orange red precipitate indicated the presence of reducing sugars. 
III. Fehling’s Test: 
Filtrates  were  hydrolyzed  with  dilute  hydrochloric  acids,  neutralized  with  
alkali  and  heated with  Fehling’s  A  and  B  solutions.  Formation of red 
precipitate indicates the presence of reducing sugars. 
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IV. Barfoed’s  test:  
1ml Barfoed’s reagent was added to 1ml of extract and heat for 2 min.Formation 
of red precipitate indicates the presence of carbohydrate. 
V. Seliwanoff’s  test: 
Plant Extract was treated with Seliwanoff’s reagent and heat strongly.Formation 
of a characteristic cherry red colour indicates the presence of keto sugar. 
F. Tests For Flavonoids 
I. Lead  acetate  test:  
 Lead acetate solution was added to small amount of extract.Formation of yellow 
precipitate indicates the presence of flavonoids. 
II. Shinoda  test:  
A  little quantity  of  extract  was dissolved  in  alcohol  with few  fragments  of  
Mg turnings  and  concentrated HCl drop wise.Formation of pink or crimson-red 
colourindicates the presence of flavonoids. 
III. Alkaline  reagent  test:  
Increasing amount of sodium hydroxide was added to the sample extract. 
Formation of yellow colouration observed which disappears upon addition of acid 
indicates the presence of flavonoids. 
IV. Ferric  chloride  test:  
Extract was treated with ferric chloride solution.Formation ofIntense green to 
black colourindicates the presence of flavonoids. 
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G. Tests  For Steroids 
I. Salkowski reaction: 2mg of dry extract was shaken with CHCl3, to the CHCl3 
layer, H2SO4 was added slowly by the sides of testtube.Formation of red 
colourindicates the presence ofsteroids. 
II. Lieberman  Burchard’s test:  2mg  of  dry  extract was  dissolved  in  acetic 
anhydride,  heated  to boiling,  cooled  and  then 1ml of conc. 
H2SO4.Formation ofred violet or green colour indicates the 
presenceofSteroids. 
4.4 Experimental animals: 
Healthy Wistar albino rats (150–200g) of either sex were used for the experiment were 
procured form the animal house of Padmavathi College of pharmacy, Dharmapuri. They were 
maintained under standard conditions (temperature 22 ±2oC, relative humidity 60 ± 5% and 
12 hr light/dark cycle). The animals werehoused in sanitized polypropylene cages containing 
sterile paddy husk as bedding.They had free access to standard pellet diet and water ad 
libitum. All the animals received human care according to the criteria outlined in the "Guide 
for the Care and Use of Laboratory Animals"prepared by the "National Academy of 
Sciences" and published by the "National Institute of Health". 
 
The hydro-alcoholic extract of P.granatum peels were subjected to the following 
Investigations: 
 
Pharmacological activities: 
1. Toxicity studies (LD50) 
2. Ulcerative colitis protective activity 
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Determination of Acute toxicity (LD50):100, 101 
The hydro alcoholic extract of the leaves ofPunica granatum Linn was dissolved in water to 
prepare a dose of 2000mg/kg b.w. of animal and administered 1ml/100g b.w. ofthe animal.
 
Acute toxicity study of the extractwas done  according  to  acute  toxic  classic  method  
(OECD  guideline  425,  2006)  using  albino female rats to determine the safe dose. 
Procedure: 
Female Albino rats weighing between 200-300g were used to carry out acute toxicity studies. 
By applying limit test method, the animals were given hydro-alcoholic extract of Punica 
granatum fruit peel in water at a dose of 2000mg/kg of body weight orally. The animals were 
continuously observed for 2-3 hrs for general behavioral, neurological, autonomic profile and 
death for a period of 24 hrs and there after once daily for 14 days. The following check list 
(Irwin’s table) was employed for the acute toxicity studies: 
1. Behavioral Profile 
Awareness: alertness, stereotypy, visual placing 
Mood: grooming, restlessness, fearfulness 
2. Neurological profile 
Motor activity: spontaneous activity, touch response, pain response, 
            Tremor, gait, grip strength, pinna reflex, corneal reflex. 
3. Autonomic profile: 
Writhing,defecation, urination, piloerection, heart rate, respiratory rate. 
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Selection and preparation of dose for pharmacological screening: 
There was no mortality and sign of toxicity at a limit dose of 2000mg/kg. Hence for 
evaluation of protective activity against colitis, two dose levels were selected in such a way 
that the lower dose (200mg/kg) was one tenth of the maximum dose and a high dose 
(400mg/kg), which was twice that of one tenth doses during acute toxicity studies for the 
ulcerative colitis protective activity. 
 
ULCERATIVE COLITIS PROTECTIVE ACTIVITY 
 
 
Chemicals and instruments 
 
All chemicals and solvents used in the study were of analytical grade. The ulcerative colitis 
inducing chemicals acetic acid (Agappe suppliers) and tri nitro benzene sulfonic acid 
(himedia suppliers) and other chemicals like Nitroblue tetrazolium, Phenazine methasulphate, 
NADH, Thiobarbituric (Himedia suppliers), used for the present study were obtained from 
Agapee distributers. 
Instruments like U.V (Shimadzu), Micro centrifuge (REMI), rotary flash evaporator 
(Superfit, Rotavap), and Microscope (Magnus), were used for the present study. 
 
 
ACETIC ACID INDUCED ULCERATIVE COLITIS IN RATS 
63
: 
 
 
EXPERIMENTAL DESIGN: 
Healthy albino rats of the either species weighing 150–200 g, will be used in the study and 
were divided into four groups with five animals in each group (n=6) as follows 
 Group I (Vehicle control) – 1 ml distilled water. 
 Group II (Experimental control) – Toxic control (2 ml acetic acid) 
 Group III (Standard) – Sulfasalazine (100 mg/kg, p.o.)+ 2mlAcetic acid 
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 Group IV (Test Low Dose) - PGPE (200 mg/ kg) + 2ml Acetic acid 
 Group V (Test High Dose) - PGPE (400 mg/ kg) + 2ml Acetic acid 
 
The experiment was performed using acetic acid for inducing colitis
82
. All the animals were 
pre-treated with the respective drugs for 8 days along with the normal diet.  On the 4th day of 
the treatment, the animals werefasted overnight with access to glucose containing water ad 
libitum. On the 5th day after 1 h of the aforementioned treatments, the animals (Groups II to 
V) wereanesthetized by ether inhalation and a polypropylene tube with 2 mm diameter were 
inserted through the rectum into the colon to a distance of 8 cm. Initially, each rat received a 
1 ml saline (0.9%) flush followed by manual palpation of the abdomen to remove any feces. 
Then, a solution of 2 ml of acetic acid (3%, v/v) in 0.9% saline wereinstilled into the lumen 
of the colon and maintained in a supine trendelenburg position for 30 s to prevent the leakage 
of the intracolonic instillate.  After 72 h of single dose administration of acetic acid (on 8th 
day), clinical activity scores weremeasured and the animals wereanaesthetized with ether and 
blood werecollected by retro orbital puncture for biochemical estimation. The animals 
weresacrificed by cervical dislocation and colon weredissected out. Colon wereflushed gently 
with saline and weighed. It is used for macroscopic scoring, histopathological and 
biochemical estimations
83
. 
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TRINITROBENZENE SULFONIC ACID (TNBS) INDUCED ULCERATIVE        
COLITIS IN RATS. 
EXPERIMENTAL DESIGN: 
Healthy albino rats of the species weighing 150–200 g, will be used in the study and were 
divided into five groups with five animals in each group (n=6) as follows. 
• Group I (Vehicle control) – 1 ml distilled water. 
• Group II (Experimental control) – Toxic control (TNBS 1 ml) 
 • Group III (Standard) –Sulfasalazine (100 mg/kg, p.o.)+ TNBS 
• Group IV (Low dose) - PGPE (200 mg/ kg) + TNBS 
 • Group V (High dose) - PGPE (400 mg/ kg) + TNBS 
The experiment was performed using TNBS for inducing colitis. All the animals will be pre-
treated with the respective drugs for 8 days along with the normal diet.  On the 4th day of the 
treatment, the animals will be fasted overnight with access to glucose containing water ad 
libitum. On the 5th day after 1 h of the aforementioned treatments, the animals (Groups II to 
V) will be anesthetized by ether inhalation and a polypropylene tube with 2 mm diameter will 
be inserted through the rectum into the colon to a distance of 8 cm. Initially, each rat received 
a 1 ml saline (0.9%) flush followed by manual palpation of the abdomen to remove any feces. 
Then, a solution of 1 ml of TNBS (dissolved in 1.0 ml 50% ethanol) will be instilled into the 
lumen of the colon and maintained in a supine Trendelenburg position for 30 s to prevent the 
leakage of the intracolonic instillate.  After 72 h of single dose administration of TNBS (on 
8th day), clinical activity scores will be measured and the animals will be anaesthetized with 
ether and blood will be collected by retro orbital puncture for biochemical estimation. The 
animals will be sacrificed by cervical dislocation and colon will be dissected out. Colon will 
be flushed gently with saline and weighed. It is used for macroscopic scoring, 
histopathological and biochemical estimations
92
. 
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Biochemical parameters estimated includes 
    1. Reduced glutathione (GSH) 
          2. Lipid peroxidation (MDA) 
         3. Myeloperoxidase (MPO) activity 
       4. Catalase (CAT) 
Preparation of colon homogenate 
The colon was quickly removed and perfused immediately with ice-cold saline(0.9% NaCl). 
A portion of the liver was homogenized in chilled Tris-HCl buffer(0.025 M, pH 7.4) using a 
homogenizer. The homogenate obtained wascentrifuged at 5000rpm for 10 min, supernatant 
was collected and used foranalysis. 
 
BIOCHEMICAL ESTIMATION: 
 
a) Estimation of reduced glutathione (GSH)102 
 
Procedure 
1g of scrapped tissue of the colon was homogenized with 10ml of 10% TCA in 
icecold condition and centrifuged at 3000rpm for 10 min. 2ml of phosphate buffer 
ofpH 8 was added to 0.5ml of supernatant. Followed by 0.2ml of DTNB solutionand 
colour intensity of yellow colour was measured immediately at 412nmagainst blank. 
Increase in absorbance (optical density) is directly proportional toconcentration of 
GSH and vice versa and % increase in GSH was calculated. 
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b) Estimation of lipid peroxidation (MDA)103 
Procedure 
Lipid peroxidation was estimated in terms of thiobarbituric acid reactivespecies 
(TBARS). One ml of the colon homogenate was added to 2.0ml of theTBA-TCA-HCl 
reagent. The contents were boiled for 15 min, cooled and centrifuged at 10000 rpm to 
remove the precipitate. The Absorbance of supernatantwas determined against blank. 
Colour intensity of pink colour chromogen wasmeasured at 535nm. Increase in the 
Absorbance indicates greater MDA anddecrease in Absorbance indicates lesser MDA 
indirectly showing lesser lipidperoxidation. Hence the Abs was measured and % 
inhibition of lipid peroxidationwas calculated. 
c) Estimation of myeloperoxidase (MPO)104 
Procedure 
Pieces of inflamed tissues (colon-4 cm) were taken. The tissue was then rinsedwith 
ice-cold saline, blotted dry, weighed and excised. Minced tissue washomogenized in 
10 volumes of ice-cold potassium phosphate buffer (pH 7.4), usingRemi tissue 
homogenizer (RQ-127A). The homogenate was centrifuged at 3500 rpmfor 30 min at 
4◦C (Remi centrifuge C23). The supernatant was discarded. 10 ml of ice-cold 50mM 
potassium phosphate buffer (pH 6.0), containing 0.5% hexadecyltrimethylammonium 
bromide (HETAB) and l0mM EDTA was then added to thepellet. It was then 
subjected to one cycle of freezing and thawing and brief period (l5s) ofsonication. 
After sonication solution was centrifuged at 15,000 rpm for 20 min. 
Myeloperoxidase(MPO)activitywasmeasuredspectrophotometrically as follows. 0.1 
ml of supernatant was combined with 2.9 ml of50mM phosphate buffer containing 
0.167 mg/ml O-dianisidine hydrochloride and0.0005% H2O2.  
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The change in absorbance was measured spectrophotometrically(Shimadzu UV 1 60A 
UV-VIS spectrophotometer), at 460 nm. One unit of MPOactivity is defined as the 
change in absorbance per minute by 1.0 at room temperature,in the final reaction. 
d) Estimation of catalase(CAT) 
Procedure 
The reaction mixture (1.5ml, vol.) contained 1.0ml of phosphate buffer, 0.1ml oftissue 
homogenate (supernatant) and 0.4ml of H2O2. The reaction was stopped bythe 
addition of 2.0ml of dichromate-acetic acid reagent and mixture was heatedfor 2 min. 
Colour intensity of green colour was measured calorimetrically at 620nm. Increase in 
Absorbance (optical density) is directly proportional toconcentration of CAT and % 
increase in CAT was calculated. 
 
HISTOPATHOLOGICAL STUDIES:
105
 
The animals were sacrificed and their colon was cut into small pieces, preservedand fixed in 
10% formalin for two days. The liver pieces were washed in runningwater for about 12 hrs, 
followed by dehydration with Isopropyl alcohol ofincreasing strength 70%, 90% and 
Absolute alcohol respectively for 12hrs each. 
 
Clearing was done in two steps 
 By using acetone with two changes (70% and Absolute) for 15-20min each. 
 By using two changes of xylene (since xylene is a good solvent for paraffin wax). 
Embedding in Paraffin by Vacuum: 
Hard paraffin was melted and the hot paraffin was poured into L-shaped blocks.The colon 
pieces were then dropped into molten paraffin quickly and allowed tocool. 
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Sectioning: 
The blocks were cut using microtome to get sections of thickness of 5µ. Thesections were 
taken on a micro-slide on which egg albumin (sticking substance)was applied. The sections 
were then allowed to remain in an oven at 60˚C for 1hr. Paraffin melts and egg albumin 
denatures, thereby fixing tissues to the slide. 
Staining: 
Eosin is an acid stain. Hence it stains all the cell constituents which are basic innature to pink 
color e.g. RNA, Cytoplasm. Haematoxylin is a basic stain whichstains all the acidic cell 
components blue e.g. DNA in nucleus. 
Statistical analysis 
All data were expressed as Mean ± SEM. The statistical Significance betweengroups were 
compared using one way ANOVA, followed by Dunnett’s (multiplecomparison test). 
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RESULTS 
Table 2: Percentage yield of PGPE was found to be 11.32 % as shown in table 2 
 
Solvent 
 
Color and consistency 
 
Method 
 
Percentage   yield 
 
Water and 
ethanol 
 
Greenish brown 
 
Hot Percolation 
 
11.32 % 
 
5.1 Preliminary phytochemical screening 
Results of the preliminary phytochemical investigation of HAPP peels are shown in the 
Table 3. 
Table 3: Preliminary phytochemical screening of PGPE 
Sl no Test Result 
 
1 Carbohydrates +ve 
2 Flavonoids +ve 
3 Glycosides +ve 
4 Steroids +ve 
5 Tannins +ve 
6 Alkaloids -ve 
5.2 DETERMINATION OF ACUTE TOXICITY 
Hydro alcoholic extract of P. granatum fruit peel was studied for acute toxicity at dose 2000 
mg/kg by p.o. route according to OECD guideline No.425. It was found to be safe up to 2000 
mg/kg body wt. by oral route. There was no mortality amongst the animals and did not show 
any toxicity or behavioral changes. The extract found to be safe or non-toxic in rats, hence 
1/10th of 2000 mg/kg and 1/5th of 2000 mg/kg were taken as low dose (200 mg/kg) and high 
dose (400 mg/kg) respectively. 
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5.3 ACETIC ACID INDUCED COLITIS IN RATS 
Instillation of acetic acid (intra-rectal route) caused inflammatory reaction in the colon. The 
inflammation covered rectum and distal colon portion. The visible changes included ulcerated 
mucosa and severe epithelial necrosis. 
Effect on antioxidant Parameters like MPO, LPO, CAT and GSH in acetic acid induced 
colitis: 
From the biochemical assays, it is found that the colitis control group animals were found to 
be significantly altered as compared to that of normal group. MPO and LPO parameters were 
increased when compared to that of normal group. But GSH and CAT were decreased when 
compared to that of normal group. 
The prophylactic treatment with sulfasalazine (100 mg/kg) showed extremely significant 
(P<0.001) decrease in MPO and LPO, and increase in GSH and CAT when compared to that 
of colitis control group. 
The animals treated with PGPE-200 showed moderately significant (p<0.01) decrease in 
MPO and LPO, and moderately significant (p<0.01) increase in CAT and less significant 
(p<0.05) increase in GSH when compared to that of colitis control group. 
The animals treated with PGPE-400 showed extremely significant (P<0.001) decrease in 
MPO and LPO, and extremely significant (P<0.001) increase in CAT, and a moderately 
significant (p<0.01) increase in GSH when compared to that of colitis control. Results are 
summarized in Table: 4 
From the histopathology result (Fig. 17), it is clear that in the normal colon (A), there was no 
tissue injury, epithelial damage and neutrophil infiltration. But in acetic acid induced colitis 
group (B), there was severe epithelial damage, tissue injury and neutrophil infiltration. In 
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case of PGPE 200, test low dose (C), there was moderate epithelial damage, tissue injury and 
neutrophil infiltration, and in PGPE 400, test high dose (D), there was less epithelial damage, 
tissue injury and neutrophil infiltration. In sulfasalazine treated group (E) there was very less 
epithelial damage, tissue injury and neutrophil infiltration. 
Table 4: Effect of sulfasalazine and PGPE on MPO, LPO, CAT, and GSH in acetic acid 
induced colitis. 
Treatment 
MPO 
Abs at 460 nm 
LPO 
Abs at 535 nm 
CAT 
Abs at 560 nm 
GSH 
Abs at 412 nm 
Normal 0.08±0.01 0.08±0.03 0.48±0.05 0.46±0.05 
Acetic acid 
control 
0.46±0.08 0.36±0.01 0.17±0.02 0.13±0.08 
Standard 
(sulfasalazine 
100 mg/kg) 
0.12±0.04 *** 0.17±0.02 *** 0.40±0.08 *** 0.34±0.02 *** 
PGPE 
200  mg 
0.38±0.02 ** 0.30±0.01 ** 0.22±0.07 ** 0.24±0.02 * 
PGPE 
400  mg 
0.22±0.04 *** 0.24±0.08 *** 0.29±0.01 *** 0.28±0.06 ** 
All the values are in absorbance ± mean, n= 6, *p<0.05 **p<0.01, ***p<0.001 one 
way ANOVA followed by Dunnett’s t test compared to positive control.   
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Fig 13: Effect of sulfasalazine and PGPE on MPO in acetic acid induced colitis: 
 
 
Fig 14: Effect of sulfasalazine and PGPE on LPO in acetic acid induced colitis: 
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Fig 15: Effect of sulfasalazine and PGPE on CAT in acetic acid induced colitis.             
 
 
Fig 16: Effect of sulfasalazine and PGPE on GSH in acetic acid induced colitis.
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             (A)                                                 (B)                                                     (C) 
                                                          
                    (D)                                                 (E) 
 
A) Normal control: normal texture of colon tissue, B) Possitive control (Acetic acid treated): Severe tissue damage and neutrophil 
infiltration. C) Low dose (PGPE-200): Moderate tissue damage and neutrophil infiltration. D) High dose (PGPE400): Mild tissue 
damage and neutrophil infiltration. E) Standard (Sulfasalazine treated): Less tissue damage and neutrophil infiltration.
Fig. 17: Effect of Sulfasalazine and PGPE on colon histology in acetic acid induced colitis. 
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5.4 TRINITROBENZENE SULFONIC ACID (TNBS) INDUCED COLITIS 
From the biochemical assays, it is found that the colitis control group animals were found to 
be significantly altered as compared to that of normal group. MPO and LPO parameters were 
increased when compared to that of normal group. But GSH and CAT parameters were 
decreased when compared to that of normal group. 
The prophylactic treatment with standard drug sulfasalazine (100 mg /kg), showed extremely 
significant (p<0.001) decrease in MPO and LPO parameters, increase in GSH and CAT 
parameters. 
The animals treated with PGPE-200 showed less significant (p<0.05) decrease in MPO and 
LPO parameters, a moderately significant (p<0.01) increase in CAT and less significant 
(p<0.05) increase in GSH. 
The animals treated with PGPE-400 Showed a moderately (p<0.01) significant  decrease in 
MPO and LPO parameters, an extremely significant (p<0.001) increase in CAT parameter 
and a moderately significant (p<0.01) increase in GSH parameter. 
From the histopathology result (Fig. 22), it is clear that in the normal colon (A), there was no 
tissue injury, epithelial damage and neutrophil infiltration. But in acetic TNBS colitis group 
(B), there was severe epithelial damage, tissue injury and neutrophil infiltration. In case of 
PGPE 200, test low dose (C), there was moderate epithelial damage, tissue injury and 
neutrophil infiltration, and in PGPE 400, test high dose (D), there was less epithelial damage, 
tissue injury and neutrophil infiltration. In sulfasalazine treated group (E) there was very less 
epithelial damage, tissue injury and neutrophil infiltration 
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Table 5: Effect of sulfasalazine and PGPE on MPO, LPO, CAT, and GSH in TNBS 
induced colitis 
 
Treatment 
MPO 
Abs at 460 nm 
LPO 
Abs at 535 nm 
CAT 
Abs at 560 nm 
GSH 
Abs at 412 nm 
Normal 0.17±0.008 0.21±0.03 0.62±0.02 0.70±0.01 
TNBS 
control 
0.56±0.017 0.65±0.01 0.21±0.01 0.47±0.02 
Standard 
(sulfasalazine 
100 mg/kg) 
0.30±0.05 *** 0.28±0.34 *** 0.52±0.04 *** 0.66±0.01 *** 
PGPE 
200  mg 
0.42±0.04 * 0.55±0.01 * 0.36±0.07 ** 0.49±0.02 * 
PGPE 
400  mg 
0.35±0.02 ** 0.51±0.08 ** 0.44±0.02 *** 0.60±0.08 ** 
All the values are in absorbance ± mean, n= 6, *p<0.05 **p<0.01, ***p<0.001 one 
way ANOVA followed by Dunnett’s test compared to positive    control.   
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         Fig 18: Effect of sulfasalazine and PGPE on MPO in TNBS induced colitis. 
 
 
           Fig 19: Effect of sulfasalazine and PGPE on LPO in TNBS induced colitis. 
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           Fig 20: Effect of sulfasalazine and PGPE on CAT in TNBS induced colitis. 
                  
 
 
           Fig 21: Effect of sulfasalazine and PGPE on GSH in TNBS induced colitis. 
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                                      (A)                                                       (B)                                                     (C) 
                                                               
                                                                   (D)                                                   (E) 
A) Normal control: normal texture of colon tissue, B) Possitive control (Acetic acid treated): Severe tissue damage and neutrophil 
infiltration. C) Low dose (PGPE-200): Moderate tissue damage and neutrophil infiltration. D) High dose (PGPE400): Mild tissue 
damage and neutrophil infiltration. E) Standard (Sulfasalazine treated): Less tissue damage and neutrophil infiltration. 
Fig .22: Effect of Sulfasalazine and PGPE on colon histology in TNBS induced colitis. 
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DISCUSSION 
 
The present study was undertaken to verify the protective effect of hydro-alcoholic extract of 
P. granatum fruit peels in colonic ulcer induced by various toxic substances like acetic acid 
and TNBS. 
The models used for the study of inflammatory bowel disease (IBD) are acetic acid induced 
ulcerative colitis and TNBS induced ulcerative colitis. Intra rectal instillation of acetic acid in 
rats affected only the distal colon portion. The inflammation was not transmural. Massive 
necrosis of mucosal and sub mucosal layers were observed. This model shares many of the 
histological features of ulcerative colitis in human beings including mucosal edema, 
neutrophil infiltration of the mucosa and sub mucosal ulceration
106
.  
The mechanism by which acetic acid produces inflammation appears to involve the entry of 
the protonated form of the acid into epithelium, where it dissociates to liberate protons 
causing intracellular acidification that most likely account for the observed epithelial injury. 
The inflammatory response initiated by acetic acid includes activation of cyclooxygenase and 
lipooxygenase pathways and generation of inflammatory mediators like prostaglandins and 
leukotrienes. Excess production of reactive oxygen metabolites e.g. superoxide, hydroxyl 
radical, hydrogen peroxide, hypochlorous acid and oxidant derivatives such as N-chloramines 
are detected in inflamed mucosa and may be pathogenic in IBD. Also, there is an increase in 
proinflammatory cytokine TNF -α production in colonic mucosa after acetic acid 
instillation
107
. 
Colitis can be induced in susceptible mouse strains by intra rectal instillation of the 
haptenating substance TNBS. Massive necrosis of mucosal and sub mucosal layers were 
observed. This model showed many of the histological features of ulcerative colitis in human 
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beings including mucosal edema, neutrophil infiltration of the mucosa and sub mucosal 
ulceration. TNBS dissolved in ethanol with or without a skin pre-sensitation step. Ethanol is 
required to break the mucosal barrier, whereas TNBS is believed to haptenize colonic 
autologous or microbiota proteins rendering them immunogenic to the host immune system. 
Histological features and an elevated production of TH2 cytokines (IL-4, IL-5 and IL-13) of 
unstimulated and αCD3/αCD28-stimulated lamina propria T cells are in these rats, in some 
aspects, similar to characteristics that have been observed in human UC
92
. 
The treatment with hydro-alcoholic extract of P. granatum fruit peel has showed a decrease 
in the macroscopic scores for the inflammation. Since the intestine is in a constant state of 
controlled inflammation, thus amplification of the inflammatory response activates 
infiltration of inflammatory cells that triggers pathological responses and symptoms of 
IBD
108
. 
Myeloperoxidase (MPO) is an enzyme mainly found in azurophilic granules of neutrophils. It 
can serve as a good marker of inflammation, tissue injury and neutrophil infiltration in 
gastrointestinal tissues. It was increased with acetic acid and TNBS. Pretreatment with P. 
granatum peels extract exhibits decrease in poly morphonuclear infiltration demonstrated by 
significant reduction in MPO activity. Oxidative damage may represent crucial pathogenic 
factor in IBD because intestinal inflammation is accompanied by increased production of 
reactive oxygen and nitrogen species
109
. 
MDA is considered as an important indicator of lipid peroxidation
110
, which is found to be 
increased in rats treated with acetic acid and TNBS. This might be due to lipid peroxidation. 
Rat pretreatment with P. granatum extract showed protection against lipid peroxidation 
characterized by significant decrease in MDA level. 
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Oxidative stress is believed to play a key role in the pathogenesis of IBD-related intestinal 
damage
111
. Intestinal mucosal damage in the IBD is related to both increased free radical 
production and a low concentration of endogenous antioxidant defence
112
. 
 
The antioxidant enzyme, catalase is the first line defensive enzyme against free radicals
113
. In 
the present study, it is decreased with acetic acid and TNBS treated groups, where as in P. 
granatum peel extract treated animals antioxidant parameter (CAT) is significantly increased. 
This shows that the P. granatum peel extract can reduce reactive free radicals that might 
cause oxidative damage to the tissues. 
 
GSH is a natural antioxidant present in the body, which is found to be decreased in rats 
treated with acetic acid and TNBS
114
. In the present study, it was observed that pretreatment 
with P. granatum peel extract exhibits elevated GSH level. 
 
Histopathology examination of drug treated group revealed less damage compared to colitis 
control group. A dose dependant decrease in MPO, MDA level is monitored, and dose 
dependant increase in GSH and CAT were also monitored. All these observations support the 
findings that the hydro-alcoholic extract of P. granatum peel is able to offer significant 
protection in both the models. The sulfasalazine treatment has shown significant protection in 
both the animal models studied.  
 
The major classes of pomegranate phytochemicals are polyphenols that predominate in 
fruits
95
. Pomegranate polyphenols include flavonoids, condensed tannins and hydrolysable 
tannins. Hydrolysable tannins (HTs) are found in the peels (rind, husk, or pericarp), 
membranes and piths of the fruit. HTs are predominant polyphenols found in pomegranate 
juice and account for 92% of its antioxidant activity
96
. 
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In the preliminary phytochemical screening, it was observed that the hydro-alcoholic extract 
of P. granatum peels contained polyphenols like glycosides, flavonoids, tannins and steroids. 
Presence of these polyphenols in the extract might attributed to their antioxidant properties, in 
turn responsible for protective effect against colitis 
On the basis of above experimental data it can be concluded that the hydro-alcoholic extract 
of P. granatum fruit peel might be useful in treating ulcerative colitis in humans.  
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CONCLUSION 
The present study concludes that hydro alcoholic extract of P. granatum peel witnessed a 
significant dose dependent ulcerative colitis protective activity in both acetic acid and TNBS 
induced experimental models.  
The ulcerative colitis protective activity was found to be more significant in high dose PGPE 
400 mg/kg compared to low dose PGPE 200 mg/kg. The P. granatum peel extract for 
ulcerative colitis protective activity was comparable with standard drug sulfasalazine. 
The hydro alcoholic extract of P. granatum fruit peel showed a dose dependant decrease in 
biomarkers like MPO and MDA and increase in GSH and CAT. From the histopathological 
study, it is clear that the P. granatum fruit peel have reversed the damage produced by acetic 
acid and TNBS.  
The ulcerative colitis protective activity of P. granatum in the experimental models may be 
due to the presence of polyphenols like flavonoids, tannins, etc, which are attributed to 
potential anti oxidant activity. 
The exact mechanism behind ulcerative colitis protective activity of hydro alcoholic extract 
of P. granatum is still unclear, further study is needed to assess exact mechanism and 
characterize the active principles responsible for ulcerative colitis protective activity. 
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SUMMARY 
The hydro-alcoholic extracts of P. granatum peels were evaluated for ulcerative colitis 
protective activity using animal models such as acetic acid induced colitis and TNBS induced 
colitis. 
Extraction and preliminary phytochemical investigation of P. granatum peels have revealed 
the presence of carbohydrates, flavonoids, glycosides, tannins and steroids. 
Acute toxicity study was performed to find out the safe dose according to OECD guidelines 
425 and hydro alcoholic extract of P. granatum peel was found to be safe at 2000 mg/kg. 
Ulcerative colitis protective activity was studied against acetic acid (3 %, 2 ml), TNBS (I ml 
in 50 % ethanol) induced ulcerative colitis, using Sulfasalazine (100 mg/ kg) body weight as 
standard reference. Biochemical parameters such as MPO, LPO, CAT, GSH and 
histopathology of colon tissue were also studied. 
Reported activity from the study showed a significant dose dependent ulcerative colitis 
protective activity for PGPE 200 and PGPE 400 is correlated with decrease in biomarkers 
like MPO and MDA and increase of GSH and CAT which showed anti oxidant activity. 
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